Editorial

November 30, 2023


Summarizing the Intentions and Outcomes of JUO 2023 Issue 3
Cheol Kwak
J Urol Oncol. 2023;21(3):181-182.

Invited Review

November 30, 2023


Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.
J Urol Oncol. 2023;21(3):183-199.

Topic Article

November 30, 2023


Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.
J Urol Oncol. 2023;21(3):200-207.

Invited Review

November 30, 2023


The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
Hyerim Ha, Joo Han Lim
J Urol Oncol. 2023;21(3):208-216.

Invited Review

November 30, 2023


Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
Chan Woo Wee, Jaeho Cho
J Urol Oncol. 2023;21(3):217-227.

Invited Review

November 30, 2023


Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
Jiwoong Yu, Hyun Hwan Sung
J Urol Oncol. 2023;21(3):228-240.

Topic Article

November 30, 2023


Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
Chung Un Lee, Wan Song, Minyong Kang, et al.
J Urol Oncol. 2023;21(3):241-248.

Original Article

November 30, 2023


Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.
J Urol Oncol. 2023;21(3):249-256.

Topic Article

November 30, 2023


Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.
J Urol Oncol. 2023;21(3):257-263.

Topic Article

November 30, 2023


Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.
J Urol Oncol. 2023;21(3):264-270.

Original Article

November 30, 2023


Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al.
J Urol Oncol. 2023;21(3):271-276.

Erratum: Addition of the second author

November 30, 2023


Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer
Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, et al.
J Urol Oncol. 2023;21(3):277-277.
Summarizing the Intentions and Outcomes of JUO 2023 Issue 3
Cheol Kwak
J Urol Oncol. 2023;21(3):181-182.

Editorial

Nov 30, 2023

Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.
J Urol Oncol. 2023;21(3):183-199.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.
J Urol Oncol. 2023;21(3):200-207.

Topic Article

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
Hyerim Ha, Joo Han Lim
J Urol Oncol. 2023;21(3):208-216.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
Chan Woo Wee, Jaeho Cho
J Urol Oncol. 2023;21(3):217-227.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
Jiwoong Yu, Hyun Hwan Sung
J Urol Oncol. 2023;21(3):228-240.

Invited Review

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
Chung Un Lee, Wan Song, Minyong Kang, et al.
J Urol Oncol. 2023;21(3):241-248.

Topic Article

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.
J Urol Oncol. 2023;21(3):249-256.

Original Article

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.
J Urol Oncol. 2023;21(3):257-263.

Topic Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.
J Urol Oncol. 2023;21(3):264-270.

Topic Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al.
J Urol Oncol. 2023;21(3):271-276.

Original Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer
Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, et al.
J Urol Oncol. 2023;21(3):277-277.
Corrects: J Urol Oncol 2022;20(1):52

Erratum: Addition of the second author

Nov 30, 2023

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043


Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: kspe.editor@gmail.com

Copyright © The Korean Urological Oncology Society.

Developed in M2PI